Fulgent Genetics (NASDAQ:FLGT) Insider Hanlin Gao Sells 939 Shares of Stock

by · The Markets Daily

Fulgent Genetics, Inc. (NASDAQ:FLGT – Get Free Report) insider Hanlin Gao sold 939 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $19.91, for a total value of $18,695.49. Following the transaction, the insider owned 987,790 shares of the company’s stock, valued at $19,666,898.90. This trade represents a 0.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Hanlin Gao also recently made the following trade(s):

  • On Tuesday, June 2nd, Hanlin Gao sold 1,688 shares of Fulgent Genetics stock. The shares were sold at an average price of $17.89, for a total value of $30,198.32.

Fulgent Genetics Stock Down 1.7%

NASDAQ:FLGT traded down $0.34 during trading hours on Friday, reaching $19.61. The company had a trading volume of 192,538 shares, compared to its average volume of 431,774. The stock has a 50-day moving average of $19.59 and a two-hundred day moving average of $18.14. Fulgent Genetics, Inc. has a one year low of $13.46 and a one year high of $31.04. The firm has a market capitalization of $539.57 million, a PE ratio of -6.95 and a beta of 0.90.

Fulgent Genetics (NASDAQ:FLGT – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.12). The company had revenue of $85.39 million for the quarter, compared to analyst estimates of $94.00 million. Fulgent Genetics had a negative return on equity of 4.93% and a negative net margin of 26.05%.Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. As a group, sell-side analysts expect that Fulgent Genetics, Inc. will post -3.48 earnings per share for the current year.

Hedge Funds Weigh In On Fulgent Genetics

Institutional investors and hedge funds have recently bought and sold shares of the business. Allworth Financial LP bought a new stake in shares of Fulgent Genetics during the second quarter worth $25,000. Farther Finance Advisors LLC raised its holdings in shares of Fulgent Genetics by 69.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock valued at $35,000 after buying an additional 548 shares during the last quarter. Kestra Advisory Services LLC bought a new position in shares of Fulgent Genetics in the fourth quarter valued at about $35,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Fulgent Genetics by 214.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock valued at $48,000 after buying an additional 1,251 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in Fulgent Genetics during the 2nd quarter worth about $38,000. Institutional investors and hedge funds own 48.06% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on FLGT shares. Wall Street Zen downgraded shares of Fulgent Genetics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Weiss Ratings raised shares of Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Finally, Piper Sandler raised their price objective on shares of Fulgent Genetics from $15.00 to $19.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $27.50.

Check Out Our Latest Report on Fulgent Genetics

Fulgent Genetics Company Profile

(Get Free Report)

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.

Featured Articles